RT Journal Article
SR Electronic
T1 The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 841
OP 848
DO 10.20892/j.issn.2095-3941.2020.0413
VO 18
IS 3
A1 Zhang, Wei
A1 Su, Liping
A1 Liu, Lihong
A1 Gao, Yuhuan
A1 Wang, Quanshun
A1 Su, Hang
A1 Song, Yuhuan
A1 Zhang, Huilai
A1 Shen, Jing
A1 Jing, Hongmei
A1 Wang, Shuye
A1 Cen, Xinan
A1 Liu, Hui
A1 Liu, Aichun
A1 Li, Zengjun
A1 Luo, Jianmin
A1 He, Jianxia
A1 Wang, Jingwen
A1 O’Connor, O. A.
A1 Zhou, Daobin
YR 2021
UL http://www.cancerbiomed.org/content/18/3/841.abstract
AB Objective: To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (Chi-CHOEP) for untreated peripheral T-cell lymphoma (PTCL).Methods: A prospective, multicenter, single arm, phase 1b/2 study was conducted. A total of 128 patients with untreated PTCL (18–70 years of age) were enrolled between March 2016 and November 2019, and treated with up to 6 cycles with the Chi-CHOEP regimen. In the phase 1b study, 3 dose levels of chidamide were evaluated and the primary endpoint was determination of the maximum-tolerated dose and recommended phase 2 dose (RP2D). The primary endpoint of the phase 2 study was 2-year progression-free survival (PFS).Results: Fifteen patients were enrolled in the phase 1b study and the RP2D for chidamide was determined to be 20 mg, twice a week. A total of 113 patients were treated at the RP2D in the phase 2 study, and the overall response rate was 60.2%, with a complete response rate of 40.7%. At a median follow-up of 36 months, the median PFS was 10.7 months, with 1-, 2-, and 3-year PFS rates of 49.9%, 38.0%, and 32.8%, respectively. The Chi-CHOEP regimen was well-tolerated, with grade 3/4 neutropenia occurring in approximately two-thirds of the patients. No unexpected adverse events (AEs) were reported and the observed AEs were manageable.Conclusions: This large cohort phase 1b/2 study showed that Chi-CHOEP was well-tolerated with modest efficacy in previously untreated PTCL patients.